This article is more than 5 years old. Information may no longer be current.

Allergan, Inamed merger given European OK

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

IRVINE, Calif. — Antitrust authorities in Germany and Spain have given their approval to Allergan’s purchase of Inamed, Allergan announced in a press release. No other approvals outside the United States are needed, the company said.

The two companies are working to complete Inamed’s divestiture of its license to Reloxin (botulinum toxin type A). Both companies remain confident that once the divestiture is complete, the U.S. Federal Trade Commission will also grant its approval, Allergan said.

In the interim, Allergan has extended the expiration date of its exchange offer for all outstanding shares of Inamed common stock. The offer now extends until Feb. 7, Allergan said in a separate release. In the exchange offer, Allergan is offering either $84 in cash or 0.8498 shares of Allergan stock for every one share of Inamed stock. More than half of Inamed’s outstanding stock had been tendered by Friday, Jan. 20, Allergan said.